Related Experiment Video
Updated: Feb 19, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Niraparib in ovarian cancer: results to date and clinical potential
Davide Caruso1, Anselmo Papa2, Silverio Tomao1
1Department of Medico-Surgical Sciences and Biotechnologies, University of Rome 'Sapienza', Latina, Italy.
Abstract:
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in patients with BRCA-mutated ovarian cancer is correlated with the concept of synthetic lethality. Among the PARP inhibitors introduced in clinical practice, niraparib showed interesting results in a phase III trial in the setting of maintenance treatment in ovarian cancer, after platinum-based chemotherapy. Interestingly, was niraparib showed to be efficacious not only in BRCA-mutated patients, but also in patients with other alterations of the homologous recombination (HR) system and in patients with unknown alterations. These results position niraparib as the first PARP-inhibitor with clinically and statistically significant results also in patients with no alterations in BRCA 1/2 and other genes involved in the DNA repair system. Even if the results are potentially practice-changing, the action of niraparib must be further studied and deepened.
Insights
Niraparib, a PARP inhibitor, shows efficacy in ovarian cancer maintenance therapy. It benefits patients with BRCA mutations and those with other DNA repair system alterations, offering new treatment possibilities.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Ovarian cancer is a leading cause of gynecological cancer death.
- Germline mutations in BRCA1/2 genes are linked to hereditary breast and ovarian cancers.
- Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for DNA damage repair via base excision repair (BER).
Purpose of the Study:
- To evaluate the efficacy of niraparib as maintenance therapy for ovarian cancer patients post-platinum-based chemotherapy.
- To investigate niraparib's effectiveness in patients with BRCA mutations and other homologous recombination (HR) system alterations.
Main Methods:
- Phase III clinical trial.
- Maintenance treatment with niraparib after platinum-based chemotherapy in ovarian cancer patients.
Main Results:
- Niraparib demonstrated significant efficacy in a phase III trial for ovarian cancer maintenance treatment.
- The drug showed benefits not only in BRCA-mutated patients but also in those with other HR system alterations or unknown genetic profiles.
- Niraparib is the first PARP inhibitor with statistically significant results in patients lacking BRCA1/2 or other DNA repair gene alterations.
Conclusions:
- Niraparib represents a significant advancement in ovarian cancer maintenance therapy.
- Its efficacy extends beyond BRCA-mutated patients, including those with other DNA repair deficiencies.
- Further research is warranted to fully elucidate niraparib's mechanisms and clinical applications.
